Edesa Biotech Income Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2012	FY 2011
Period Ending	Mar '26 Mar 31, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Aug '12 Aug 31, 2012	Aug '11 Aug 31, 2011
Revenue	-	-	-	0.29	0.7
Revenue Growth (YoY)	-	-	-	-58.97%	-
Gross Profit	-	-	-	0.29	0.7
Selling, General & Admin	3.74	4.24	4.13	2.56	1.91
Depreciation & Amortization Expenses	-	-	-	0.11	0.09
Research & Development	4.93	3.67	2.88	1.83	0.83
Other Operating Expenses	-	-	-	1.88	1.7
Total Operating Expenses	8.67	7.91	7.01	6.37	4.52
Operating Income	-9.78	-7.91	-7.01	-6.09	-3.82
Interest Income	0.02	0	0.15	0	0.01
Other Non-Operating Income (Expense)	0.47	0.72	0.69	1.32	1.22
Total Non-Operating Income (Expense)	0.49	0.73	0.85	1.33	1.24
Pretax Income	-9.29	-7.18	-6.17	-5.2	-3.6
Provision for Income Taxes	0	0	0	0	0
Net Income	-9.29	-7.19	-6.17	-5.2	-3.6
Net Income to Common	-9.29	-7.19	-6.17	-5.2	-3.6
Shares Outstanding (Basic)	8	6	3	0	0
Shares Outstanding (Diluted)	8	6	3	0	0
Shares Change (YoY)	102.32%	77.54%	21373.90%	14.93%	-
EPS (Basic)	-1.34	-1.27	-1.93	-352.80	-264.60
EPS (Diluted)	-1.34	-1.27	-1.93	-352.80	-264.60
Shares Outstanding	8.89	7.14	3.25	0.02	-
Free Cash Flow	-6.76	-7.32	-4.89	-4.03	-2.93
Free Cash Flow Per Share	-0.88	-1.29	-1.53	-270.40	-225.98
Gross Margin	-	-	-	100.00%	100.00%
Operating Margin	-	-	-	-2127.67%	-548.27%
Profit Margin	-	-	-	-1816.68%	-515.97%
FCF Margin	-	-	-	-1407.48%	-419.91%
EBITDA	-9.7	-7.79	-6.83	-5.97	-3.74
EBITDA Margin	-	-	-	-2088.46%	-535.74%
EBIT	-9.78	-7.91	-7.01	-6.09	-3.82
EBIT Margin	-	-	-	-2127.67%	-548.27%
Effective Tax Rate	-0.01%	-0.01%	-0.01%	-0.02%	-0.02%

Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q